Voting Rights and Shares Capital of the Company
Nanobiotix (Euronext Paris / Nasdaq: NBTX) reported its share capital and voting rights as of June 30, 2026, in accordance with French regulations (articles L.233-8 II of the French Commercial Code and 223-16 of the AMF General Regulation).
Rhea-AI Summary
Nanobiotix (Euronext Paris / Nasdaq: NBTX) reported its share capital and voting rights as of June 30, 2026, in accordance with French regulations (articles L.233-8 II of the French Commercial Code and 223-16 of the AMF General Regulation).
According to Nanobiotix, the company had 50,825,682 shares outstanding, corresponding to 54,486,890 theoretical (gross) voting rights and 54,464,772 exercisable (net) voting rights. The theoretical voting rights figure includes shares with suspended rights, while the exercisable voting rights exclude shares held in treasury.
Positive
- None.
Negative
- None.
Details
News Market Reaction – NBTX
In the Jul 31 session, NBTX declined 4.41%, reflecting a moderate negative market reaction. Argus tracked a peak move of +2.4% during that session. Argus tracked a trough of -3.8% from its starting point during tracking. Our momentum scanner triggered 12 alerts that day, indicating notable trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
- Reporting date
- June 30, 2026
- Share capital and voting rights disclosure
- Shares outstanding
- 50,825,682 shares
- As of June 30, 2026
- Theoretical voting rights
- 54,486,890 voting rights
- As of June 30, 2026
- Exercisable voting rights
- 54,464,772 voting rights
- As of June 30, 2026
- Patent families
- More than 30 patent families
- Company description
- Nanotechnology platforms
- Three nanotechnology platforms
- Company description
- Incorporation year
- 2003
- Company history
Historical Context
-
Reported May share capital and theoretical and exercisable voting rights.
-
Reported clinical progress, financing completion, and cash supporting operations into 2029.
-
Joined the Euronext Tech Leaders segment and Euronext Tech Leaders Index.
-
Closed a global offering raising approximately $100 million in gross proceeds.
-
Underwriters fully exercised the over-allotment option, increasing offering proceeds.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
isin code financial
theoretical voting rights regulatory
exercisable voting rights regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
PARIS, July 30, 2026 (GLOBE NEWSWIRE) -- In accordance with articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers)
Paris, France, July 30, 2026
Market: Euronext Paris / Nasdaq
Euronext Compartment: B
ISIN code: FR0011341205
Nasdaq: NBTX
Bloomberg: NANO:FP
Reuters: NANO.PA
Website: www.nanobiotix.com
| Date | Number of Shares Outstanding | Total number of voting rights | |
| Total voting rights, theoretical1 | Total voting rights, exercisable2 | ||
| June 30, 2026 | 50,825,682 | 54,486,890 | 54,464,772 |
***
About NANOBIOTIX
Nanobiotix is a late-stage clinical biotechnology company pioneering disruptive, physics-based therapeutic approaches to revolutionize treatment outcomes for millions of patients; supported by people committed to making a difference for humanity. The Company’s philosophy is rooted in the concept of pushing past the boundaries of what is known to expand possibilities for human life.
Incorporated in 2003, Nanobiotix is headquartered in Paris, France and is listed on Euronext Paris since 2012 and on the Nasdaq Global Select Market in New York City since December 2020. The Company has a subsidiary in Cambridge, Massachusetts (United States).
Nanobiotix is the owner of more than 30 patent families associated with three (3) nanotechnology platforms with applications in 1) oncology; 2) bioavailability and biodistribution; and 3) disorders of the central nervous system.
For more information about Nanobiotix, visit us at www.nanobiotix.com or follow us on LinkedIn and Twitter.
Contacts
| Nanobiotix | ||
| Communications Department Brandon Owens VP, Communications +1 (617) 852-4835 contact@nanobiotix.com | Investor Relations Department Joanne Choi VP, Investor Relations (US) +1 (713) 609-3150 Ricky Bhajun Director, Investor Relations (EU) investors@nanobiotix.com | |
| Media Relations | ||
France – HARDY Caroline Hardy +33 06 70 33 49 50 carolinehardy@outlook.fr | Global – uncapped Becky Lauer +1 (646) 286-0057 uncappednanobiotix@uncappedcommunications.com | |
1 The total number of theoretical (or “gross”) voting rights is used as the basis for calculating threshold crossings. In accordance with Article 223-11 of the AMF General Regulations, this number is calculated on the basis of all shares to which voting rights are attached, including those for which voting rights have been suspended.
2 The total number of exercisable at a shareholders’ meeting (or “net”) voting rights is calculated without taking into account shares for which voting rights have been suspended as shares held in treasury by the Company. It is released in order to ensure that the public is properly informed.
Attachments
- 2026-07-30 -- NBTX -- Voting Rights & Shares Capital -- FINAL
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.